To better predict the mechanism of action for candidate AD therapeutics, the current study was specifically designed to test the effect of BACE1 inhibitors, γ-secretase inhibitors (GSI), and γ-secretase modulators (GSM) on amyloid homeostasis. The gene discussed is BACE1; the disease is Alzheimer disease.